
RenalytixAI and Joslin Diabetes Center Build on Proprietary Kidney Biomarker Portfolio for KidneyIntelX Platform
NEW YORK, April 14, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) announced today that it has entered into an exclusive option agreement with Joslin Diabetes Center for patent filings on certain additional novel biomarkers in kidney …